

SCHEDULE 8

Consequential provision

PART 2

Amendment of secondary legislation

Amendment of the Branded Health Service Medicines (Costs) Regulations 2018

16.—(1) The Branded Health Service Medicines (Costs) Regulations 2018^{M1} are amended as follows.

(2) In regulation 1(2) (interpretation)—

^{F1}(a)

^{F1}(b)

^{F1}(c)

^{F1}(d)

(e) in the definition of “supplementary protection certificate” omit from “means” to the end and insert “ has the meaning given by section 128B(2) of the Patents Act 1977 ”.

^{F2}(3)

(4) In regulation 9 (new presentation)—

(a) in paragraph (10)—

^{F3}(i)

^{F4}(ii) in sub-paragraph (b), after “Article 21” insert “or regulation 64(6) of the 2012 Regulations”; and]

^{F5}(b)

^{F6}(5)

^{F7}(6)

Textual Amendments

F1 Sch. 8 para. 16(2)(a)-(d) omitted (31.12.2020 immediately before IP completion day) by virtue of [The Human Medicines \(Amendment etc.\) \(EU Exit\) Regulations 2020 \(S.I. 2020/1488\)](#), reg. 1, **Sch. 2 para. 194(d)(i)**

F2 Sch. 8 para. 16(3) omitted (31.12.2020 immediately before IP completion day) by virtue of [The Human Medicines \(Amendment etc.\) \(EU Exit\) Regulations 2020 \(S.I. 2020/1488\)](#), reg. 1, **Sch. 2 para. 194(d)(ii)**

F3 Sch. 8 para. 16(4)(a)(i) omitted (31.12.2020 immediately before IP completion day) by virtue of [The Human Medicines \(Amendment etc.\) \(EU Exit\) Regulations 2020 \(S.I. 2020/1488\)](#), reg. 1, **Sch. 2 para. 194(d)(iii)**

F4 Sch. 8 para. 16(4)(a)(ii) substituted (31.12.2020 immediately before IP completion day) by [The Human Medicines \(Amendment etc.\) \(EU Exit\) Regulations 2020 \(S.I. 2020/1488\)](#), reg. 1, **Sch. 2 para. 194(d)(iv)**

F5 Sch. 8 para. 16(4)(b) omitted (31.12.2020 immediately before IP completion day) by virtue of [The Human Medicines \(Amendment etc.\) \(EU Exit\) Regulations 2020 \(S.I. 2020/1488\)](#), reg. 1, **Sch. 2 para. 194(d)(v)**

Changes to legislation: There are currently no known outstanding effects for the The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019, Paragraph 16. (See end of Document for details)

- F6** Sch. 8 para. 16(5) omitted (31.12.2020 immediately before IP completion day) by virtue of [The Human Medicines \(Amendment etc.\) \(EU Exit\) Regulations 2020 \(S.I. 2020/1488\)](#), reg. 1, **Sch. 2 para. 194(d)(vi)**
- F7** Sch. 8 para. 16(6) omitted (31.12.2020 immediately before IP completion day) by virtue of [The Human Medicines \(Amendment etc.\) \(EU Exit\) Regulations 2020 \(S.I. 2020/1488\)](#), reg. 1, **Sch. 2 para. 194(d)(vii)**

Commencement Information

- I1** Sch. 8 para. 16 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, **Sch. 5 para. 1(1)**), see reg. 1

Marginal Citations

- M1** [S.I. 2018/345](#).

Changes to legislation:

There are currently no known outstanding effects for the The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019, Paragraph 16.